Inogen, Inc. Securities Litigation (2019)

If you purchased a significant amount of shares of Inogen, Inc (NASDAQ: INGN), you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:Inogen, Inc
Date Filed:March 6th, 2019
Sector:Health Care
Industry:Industrial Specialties

According to the Complaint, Inogen is a medical technology company.

The Complaint alleges that during the Class Period, Defendants made false and misleading statements and/or failed to disclose adverse information regarding Inogen's business metrics and financial prospects. Specifically, the Complaint alleges Defendants failed to disclose that: (i) Inogen had overstated the true size of the total addressable market ("TAM") for its portable oxygen concentrators and had misstated the basis for its calculation of the TAM; (ii) Inogen had falsely attributed its sales growth to the strong sales acumen of its salesforce, when in reality it was due in large part to sales tactics designed to deceive its elderly customer base; (iii) the growth in Inogen's domestic business-to-business sales to home medical equipment ("HME") providers was inflated, unsustainable and was eroding direct-to-consumer sales; and (iv) very little of Inogen's business was actually coming from the more stable Medicare market.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Inogen, Inc

First Identified Complaint

William Fabbri, et al. v. Inogen, Inc., et al.

Date Filed:March 6th, 2019
Class Period Start:November 8th, 2017
Class Period End:February 26th, 2019
First Identified Complaint Filings
#Document TitleFiling Date